Omicron sublineage (parent sublineage) | Therapeutic/prophylactic monoclonal antibodies | |||
Tixagevimab-cilgavimab (no longer recommended) | Bebtelovimab (no longer recommended) | Sotrovimab (no longer recommended) | Casirivimab-imdevimab (no longer recommended) | |
BA.1 | Reduced activity | Active | Active | Inactive |
BA.2 | Active | Active | Inactive | Inactive |
BA.4/BA.5 | Reduced activity | Active | Inactive | Inactive |
BA.4.6 (BA.4) | Inactive | Likely active | Inactive | Inactive |
BA.2.75.2 (BA.2) | Inactive* | Likely active | Inactive | Inactive |
BQ.1/BQ.1.1 (BA.5) | Inactive | Inactive | Inactive | Inactive |
XBB/XBB.1/XBB.1.5 (BA.2.10.1 and BA.2.75 recombinant) | Inactive | Inactive | Inactive | Inactive |
"Variants of Concern" have evidence of an increase in transmissibility, greater risk of severe disease, a significant reduction in neutralization by antibodies generated during previous infection or vaccination, or reduced effectiveness of treatments or vaccines. Since 2022, Omicron (B.1.1.529) variants within evolving sublineages have been the predominant circulating variants globally. Prior Variants of Concern that are no longer circulating are the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) variants.
In the United States, the proportion of circulating variants in each state can be found on the CDC website.
Predicted activity of monoclonal antibodies against various SARS-CoV-2 variants is based on neutralizing assays that use pseudoviruses bearing the key spike protein mutations found in each variant. Neutralizing data are emerging for certain Omicron sublineages and are thus uncertain.CDC: United States Centers for Disease Control and Prevention.
* For a related sublineage, BA.2.75, tixagevimab-cilgavimab appears to retain neutralizing activity.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟